Summary
Wall Street Analysts Predict a 28.3% Upside in ABSCI CORP (ABSI): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 28.3% in ABSCI CORP (ABSI). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Here's Why Absci Corporation (ABSI) is a Great Momentum Stock to Buy
Does Absci Corporation (ABSI) have what it takes to be a top stock pick for momentum investors? Let's find out.
ABSI Soars 36% on Positive Interim Update From Phase I Hair Loss Study
Absci stock jumps 36% as interim phase I hair loss study data show ABS-201 is well tolerated and pharmacokinetics support the potential for infrequent dosing.
Absci Corporation Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| TMB Timothy M. Bidwell Hazlett, BURT & WATSON Inc. | 200 | $524 | $1,984 | $1,460 | 278.63% |
| CE Curtis Ellergodt Rothschild Investment LLC | 105 | $263.81 | $1,041.6 | $777.79 | 294.83% |
| BG Bart Gancher Intech Investment Management LLC | 31,973 | $80,981.31 | $315,253.78 | $234,272.47 | 289.29% |
 John H. Burbank III Passport Capital LLC | 2.13M | $7.45M | $21.05M | $13.6M | 182.52% |
| YA Yinka Akinsola Blue Trust Inc. | 100 | $251 | $976 | $725 | 288.84% |
Absci Corporation (ABSI) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Absci Corporation ever had a stock split?
Absci Corporation Profile
| Biotechnology Industry | Healthcare Sector | Sean McClain CEO | NASDAQ (NGS) Exchange | 00091E109 CUSIP |
| US Country | 140 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Absci Corporation is positioned at the forefront of the pharmaceutical industry as a pioneering data-first generative artificial intelligence (AI) drug creation company based in the United States. Founded in 2011 and headquartered in Vancouver, Washington, Absci sets itself apart by integrating AI with scalable wet laboratory technologies. This unique fusion is geared towards the expeditious creation of biologic drugs aimed at addressing patients' needs across various conditions. The company’s innovative approach aims to enhance the traditional biologic drug discovery process. By leveraging AI, it seeks to concurrently optimize several drug attributes critical to development and therapeutic efficacy. Absci has also established a collaborative effort with the Memorial Sloan Kettering Cancer Center, focusing on the discovery of novel therapeutics through the use of generative AI, underscoring its commitment to advancing medical research and treatment.
Products and Services
- Integrated Drug Creation Platform
This flagship offering by Absci harnesses the power of generative AI in conjunction with scalable wet lab technologies to revolutionize the biologic drug discovery process. The platform is meticulously designed to optimize multiple drug characteristics simultaneously, significantly improving the efficiency and efficacy of developing therapeutic biologics. This holistic approach not only accelerates the pipeline of drug discovery but also ensures that the drugs developed are of high therapeutic potential, catering to the nuanced needs of patients.
- Collaborative Research in Therapeutic Discovery
The partnership with Memorial Sloan Kettering Cancer Center showcases Absci's dedication to leveraging its generative AI and wet lab expertise in the quest for groundbreaking therapeutics. By working closely with a leading cancer research institution, Absci not only extends its scientific prowess into oncology but also enriches its drug discovery platform with valuable insights into cutting-edge cancer treatments. This collaboration represents a strategic effort to fuse AI’s predictive capabilities with clinical insights, aiming to uncover novel therapeutic pathways and options for patients.
